Results of this secondary analysis of the REPRIEVE randomized clinical trial suggest that PCOLCE may be associated with the atherosclerotic plaque stabilization effects of statins by promoting collagen deposition in the extracellular matrix transforming vulnerable plaque phenotypes to more stable coronary lesions. ClinicalTrials.gov Identifier: NCT02344290.

P2, N=161, Completed, Charite University, Berlin, Germany | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Jun 2024 | Trial primary completion date: Feb 2025 --> Jun 2024

Our data suggest that the cholesterol synthetic flow and CoA content may be limited in statin-sensitive cancer cells. We also suggest that CoA synthesis and cholesterol storage may fluctuate with atorvastatin treatment in statin-sensitive cancer cells.

Moreover, atorvastatin slowed the progression of lung tissue histological lesions. Collectively, the present study suggests that, atorvastatin effectively protects against LPS-induced acute lung injury through inhibition of oxidative stress, inflammation, hypoxia, and neutrophil recruitment.

For the in vitro study, an MTT assay was performed, and then different combinations against the THP-1 cell line were used as follows: non-treated cells, THP-1/ATOR IC50, THP-1/cytarabine (CYT) IC50, THP-1/doxorubicin (DOX) IC50, THP-1/DOX/CYT, THP-1/ATOR/CYT, THP-1/ATOR/DOX, and THP-1/ATOR/CYT/DOX...G4 was treated with Bevacizumab (Bev) (5 mg/kg)...Furthermore, in vivo co-treatment with ATOR/Bev decreased tumor incidence and size with a significant reduction of the immunohistochemical PCNA (LI%) in lung parenchyma, targeting PI3K/Akt/mTOR, and VEGF-A signaling pathways. Co-treatment with ATOR and chemotherapies led to cell cycle arrest, modulation of the PI3K/Akt/mTOR, and VEGF-A signaling pathways in tumor cells.

Molecular docking analysis revealed that atorvastatin binds to CYP2C9 with a binding energy of - 8.837, indicating highly stable binding. CYP2C9 is associated with the prognosis of HCC patients and could serve as a potential target for atorvastatin treatment in HCC.

Simvastatin was identified as a potential drug, reversing EMT induced by XBP1+ mast cells in pan-cancer. Aberrant activation of MEK/ERK signaling in XBP1+ mast cells can stimulate cancer cell EMT by modulating degranulation, while Simvastatin can inhibit EMT by suppressing degranulation.

P1, N=20, Not yet recruiting, Stanford University | Initiation date: Sep 2024 --> Nov 2024

P2, N=12, Not yet recruiting, Beijing Inno Medicine Co., Ltd.

P=N/A, N=5047, Completed, Yuhan Corporation | Active, not recruiting --> Completed

P3, N=145, Recruiting, Ain Shams University

P4, N=137, Completed, Organon and Co | Active, not recruiting --> Completed

P1, N=80, Recruiting, Pfizer | N=40 --> 80

In this study, we present an in-depth exploration of the potential to repurpose two generic, safe drugs for mCRPC treatment, valproic acid (VPA) and simvastatin (SIM), which already show antitumor efficacy in combination, primarily affecting the cancer stem cell compartment via MVP/YAP axis modulation. Bioinformatics analysis of the LC‒MS/MS and 1H‒NMR metabolomics/lipidomics results confirmed the specific impact of VPA/SIM on Hippo-YAP.

P1/2, N=130, Recruiting, Beijing Inno Medicine Co., Ltd. | Trial completion date: Nov 2024 --> Apr 2025

P1, N=64, Completed, Beijing Inno Medicine Co., Ltd. | Recruiting --> Completed

Adding atorvastatin calcium to amlodipine therapy significantly improves clinical outcomes and reduces serum inflammatory marker levels in elderly patients with hypertension. This combination therapy is considered safe and may be recommended for broader clinical application.

Our study sheds light on the paradigm of "Exercise is Medicine", providing evidence to support the use of statins combined with exercise in reducing LDL-C levels, and unveils potential avenues for clinical applications of sEH inhibitors, presenting novel prospects for therapeutic interventions in ASCVD.

P=N/A, N=300, Recruiting, Nanjing Medical University | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P4, N=78, Not yet recruiting, National University Hospital, Singapore

P1, N=69, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting

P=N/A, N=2000, Not yet recruiting, Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

P1/2, N=46, Not yet recruiting, Assiut University

P4, N=119, Completed, University of Kansas Medical Center | Active, not recruiting --> Completed

P4, N=240, Active, not recruiting, Chiayi Christian Hospital | Recruiting --> Active, not recruiting

P=N/A, N=300, Active, not recruiting, Assiut University

P=N/A, N=1092, Not yet recruiting, Dalian Municipal Central Hospital; Dalian Municipal Central Hospital

P=N/A, N=302, Not yet recruiting, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University; The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University

P=N/A, N=100, Completed, Riphah International University

A 65-year-old woman with a past medical history of hyperlipidemia on atorvastatin for four years, type 2 diabetes, sciatica, and a prior history of endometrial cancer, presented to the emergency department due to proximal muscle weakness worsening over 2-3 months...During her hospital course, she was started on prednisone, fluids, and intravenous immunoglobulin (IVIG). Once completing two days of IVIG, the patient was discharged to rehab with rheumatology follow-up. The purpose of this case is to elucidate a rare side effect of a medication despite being on it for several years and to increase awareness and attention to an adverse effect that may one day lead to stratifying patients' risk on the medication.

The obtained qRT-PCR and proteomics data highlight the modulation of cell death via apoptosis (BAX/BCL2, CASP9) and autophagy (BECN1, BNIP3, BNIP3L and LC3B), as well as an epithelial to mesenchymal transition blockage (HTRA1, SERPINE1, WNT5A, ALDH3B1 and EPHA2) and remodeling of the extracellular matrix (VCAN, SERPINE1 and TGFBI). Overall, these results lay the foundation for further investigations on the potential combinatory clinical treatment with temozolomide.

P1/2, N=22, Enrolling by invitation, Johns Hopkins University | Not yet recruiting --> Enrolling by invitation

Atorvastatin, dexamethasone, and PGE2 differentially modulated these inflammatory changes. ACO/eCOPD is associated with viral infection and an inflammatory milieu. Therapeutic strategies using statins and inhaled corticosteroids are recommended to control these pathogenic changes.

The multifunctional QO/@PV@AB7 hydrogel was prepared by incorporating pravastatin-loaded chitosan nanoparticles (CSNPs@PV, 2 mg/mL) and antimicrobial peptide AMP-AB7 loaded silica nanoparticles (SiO2NPs@AB7, 0.5 mg/mL)...Notably, it also demonstrates potent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli. Additionally, in vivo experiments demonstrated that the hydrogel exhibited accelerated wound healing in MRSA-infected diabetic foot ulcers, with a reduction of four days compared to the control group.

P1/2, N=80, Active, not recruiting, University of Chicago | Trial completion date: Jun 2025 --> Mar 2025

Thus, our study presents PUMP as a novel and promising bioactive vesicular nanosystem with potential synergistic effect with ATV or other antitumor drugs. PUMP-integrated MN could be considered a promising platform for future applications in localized breast cancer therapy.

Induced synthesis of endogenous 2'3'-cGAMP by intrabreast tumor bacterium S. aureus infection or low-dose doxorubicin treatment facilitates cell migration depending on the cGAS/cGAMP/Rab18/FosB signaling. We find that lovastatin induces Rab18 deprenylation that abolishes 2'3'-cGAMP recognition therefore suppressing cell migration. Together, our study reveals a previously unidentified 2'3'-cGAMP function in cell migration control via the 2'3'-cGAMP/Rab18/FosB signaling that provides additional insights into clinical applications of 2'3'-cGAMP.

P1/2, N=80, Active, not recruiting, University of Chicago | Trial primary completion date: Dec 2024 --> Jul 2024

P1, N=28, Completed, AstraZeneca | Recruiting --> Completed

P1, N=30, Recruiting, Children's Hospital Medical Center, Cincinnati | N=20 --> 30

Furthermore, we propose metabolomic analysis to uncover the drug's mechanisms of action and computational methods like molecular docking to predict its potential targets, which could refine drug design and inform personalized treatment strategies. Our commentary aims to refine the study's conclusions and encourage research that maximizes the understanding and clinical management of chemotherapy-induced cardiotoxicity.

No abstract available